Pharmacokinetics, safety and tolerability of the selective JAK1 inhibitor, ABT-494, in healthy volunteers and subjects with rheumatoid arthritis

Authors
Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2015
This article has no abstract
Epistemonikos ID: 535648cab8a71fec5ec27607703876e7d9049d01
First added on: Jan 28, 2022